10/10/2007

The FDA will allow three generic drugmakers to launch their versions of Novartis AG's epilepsy treatment Trileptal. Boehringer Ingelheim subsidiary Roxane Laboratories, Glenmark Pharmaceuticals Ltd. and Sun Pharmaceutical Industries Ltd. received FDA approval.

Full Story:
CNNMoney, Bloomberg1

Related Summaries